Jove
Visualize
Contact Us

Related Experiment Videos

[Are estrogens carcinogens?].

G Emons1, C Gründker, V Hanf

  • 1Klinik für Gynäkologie und Geburtshilfe, Georg-August-Universität Göttingen. emons@med.uni-goettingen.de

Zentralblatt Fur Gynakologie
|June 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review.

Archives of gynecology and obstetrics·2021
Same author

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.

Journal of cancer research and clinical oncology·2021
Same author

Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review.

Archives of gynecology and obstetrics·2020
Same author

Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review.

Archives of gynecology and obstetrics·2020
Same author

[S3 guidelines on the diagnosis and treatment of carcinoma of the endometrium : Requirements for pathology].

Der Pathologe·2019
Same author

Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centres.

European journal of cancer (Oxford, England : 1990)·2017
Same journal

About 150 births naturally after previous Caesarean section.

Zentralblatt fur Gynakologie·2010
Same journal

About lutein cysts found in hydrops foetus et placentae.

Zentralblatt fur Gynakologie·2010
Same journal

The potencies of the burner epithelium, especially a tendency to form serous epitrel, squamous and mucosal epithelium.

Zentralblatt fur Gynakologie·2010
Same journal

Two double birth defects causing obstetric difficulties.

Zentralblatt fur Gynakologie·2010
Same journal

The uterine size and fundus level in the first part of pregnancy.

Zentralblatt fur Gynakologie·2010
Same journal

The crossbar interposition.

Zentralblatt fur Gynakologie·2010
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Estrogens, particularly their metabolites, may damage DNA and increase cancer risk. While hormone therapy is still recommended for some, limiting its use and duration is advised.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Context:

  • Estrogens are known tumor promoters, potentially increasing cancer risk through receptor-mediated pathways.
  • Recent research suggests estrogen metabolites, like 4-hydroxyestrogens, possess genotoxic properties.
  • Associations between estrogen exposure and endometrial, breast, and ovarian cancer risk are well-established or hypothesized.

Purpose:

  • To explore the genotoxic potential of estrogen metabolites.
  • To investigate the role of estrogen metabolism in cancer development.
  • To inform clinical practice regarding hormone replacement therapy.

Summary:

  • Estrogens are implicated in tumor promotion via estrogen-receptor-mediated mitogenic activity.
  • Emerging evidence indicates that estrogen metabolites can induce DNA damage and mutations.

Related Experiment Videos

  • Molecular-epidemiologic studies suggest individual variations in estrogen metabolism may influence cancer risk.
  • These genotoxic properties of estrogens warrant further clinical investigation.

    • Impact:

    • Findings may lead to novel preventive strategies for hormone-related cancers.
    • Highlights the importance of considering individual estrogen metabolism in cancer risk assessment.
    • Supports a cautious approach to hormone replacement therapy, recommending its restriction to symptomatic women with clear indications and temporary use.